Repros Therapeutics (RPRX) versus Puma Biotechnology (PBYI) Head-To-Head Comparison
Repros Therapeutics (NASDAQ: RPRX) and Puma Biotechnology (NYSE:PBYI) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, profitability, analyst recommendations, institutional ownership, valuation and dividends.
This table compares Repros Therapeutics and Puma Biotechnology’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional and Insider Ownership
14.5% of Repros Therapeutics shares are owned by institutional investors. Comparatively, 81.0% of Puma Biotechnology shares are owned by institutional investors. 2.5% of Repros Therapeutics shares are owned by company insiders. Comparatively, 22.7% of Puma Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Repros Therapeutics and Puma Biotechnology’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Repros Therapeutics||N/A||N/A||-$15.95 million||($0.63)||-0.51|
|Puma Biotechnology||N/A||N/A||-$289.01 million||($8.16)||-14.68|
Puma Biotechnology is trading at a lower price-to-earnings ratio than Repros Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Repros Therapeutics has a beta of 0.44, meaning that its stock price is 56% less volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500.
This is a summary of recent ratings and price targets for Repros Therapeutics and Puma Biotechnology, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Repros Therapeutics presently has a consensus target price of $1.50, suggesting a potential upside of 368.75%. Puma Biotechnology has a consensus target price of $113.11, suggesting a potential downside of 5.54%. Given Repros Therapeutics’ higher possible upside, analysts clearly believe Repros Therapeutics is more favorable than Puma Biotechnology.
Puma Biotechnology beats Repros Therapeutics on 7 of the 11 factors compared between the two stocks.
About Repros Therapeutics
Repros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. The Company’s Proellex product candidate for female reproductive health is a chemical entity, which acts as a selective blocker of the progesterone receptor. It is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis The Company has an active Investigational New Drug (IND) for the vaginal delivery of Proellex for the treatment of uterine fibroids.
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment of patients with HER2 positive metastatic breast cancer. It focuses on developing neratinib as an intravenously administered agent. The intravenous version of neratinib resulted in exposure levels of neratinib in pre-clinical models. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors.
Receive News & Ratings for Repros Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repros Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.